MGI Pharma announced the acquisitio...
MGI Pharma announced the acquisition of Zyco and Aesgen in September. The $50 million cash acquisition of Zycos' oncology and antiviral programs includes ZYC101a, which not long ago completed phase 2 trials. For $32 million cash, MGI also acquired Aesgen, a company focused forward treating ...
|